Every Form 4 that Abbott Labs (ABT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABT filings page.
ABBOTT LABORATORIES (ABT) officer John A. McCoy Jr., Vice President and Controller, reported share dispositions in early September 2026.
On September 2, 2026 he sold 27 common shares at $109.54 per share in a sale described as an open market or private transaction. On September 1, 2026, 52 common shares were delivered or withheld for payment of exercise price or tax liability at $110.36 per share. A separate entry shows 59 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust, described as a Profit Sharing Trust, as of September 1, 2026. No Rule 10b5-1 trading plan is reported for these transactions.
ABBOTT LABORATORIES (ABT) executive vice president and chief financial officer Philip P. Boudreau reported a Form 4 showing that on September 1, 2026, 388 common shares were disposed of at $110.36 per share to satisfy exercise price or tax liability obligations. After this withholding, he holds 70,784 common shares directly, plus indirect holdings of 9,332 shares in the Abbott Laboratories Stock Retirement (Profit Sharing) Trust and 2,200 shares held by his spouse. No Rule 10b5-1 trading plan is affirmed.
ABBOTT LABORATORIES (ABT) reported insider transactions by Chairman and CEO Robert B. Ford on 2026-08-25. He exercised employee stock options covering 398,832 common shares (151,869 at a $44.40 exercise price and 246,963 at $59.94), then sold a total of 398,832 common shares in open-market transactions at volume-weighted average prices in the $115–$116 range. In addition, 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
Abbott Laboratories executive Louis H. Morrone, Executive Vice President, reported transactions in common shares. On August 11, 2026, he sold 5,850 common shares in a non-derivative transaction at $109.83 per share, leaving 70,724 common shares held directly. On August 12, 2026, a discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares in a Profit Sharing Trust at $107.99 per share, leaving no shares reported under that indirect ownership.
ABBOTT LABORATORIES director John G. Stratton reported a compensation-related grant of stock-based units, not an open-market trade. On the reported date, he acquired 432 stock equivalent units tied to Abbott common shares at a reference value of $90.74 per unit. These units represent director fees credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash around age 65 or upon retirement from the board.
The stock equivalent units earn the same return as if the fees were invested in Abbott shares and the reported balance also reflects units accumulated through a dividend reinvestment feature. Following this grant, Stratton’s account holds a total of 14,022 stock equivalent units.
Roman Michael F reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 416 stock equivalent units as compensation. These units were credited on 2026-06-30 at a reference price of $90.74 per unit and are tied to director fees.
The stock equivalent units track the return Abbott shares would have earned, but are paid out in cash, generally at age 65 or when the director retires from the board. After this award, Roman holds a total of 6,746 stock equivalent units, including amounts accumulated through a dividend reinvestment feature.
Abbott Laboratories director Patricia Paola Gonzalez received a compensation-related grant of derivative securities. She acquired 363 Stock Equivalent Units on Common Shares at a reference value of $90.74 per unit, increasing her directly held stock equivalent unit balance to 5,963 units. These units are credited as director fees into a stock equivalent unit account under a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board, earning the same return as if invested in Abbott shares.
Abbott Laboratories director Kevin T. Conroy reported a compensation-related award of stock equivalent units. On this Form 4, he acquired 231 stock equivalent units at a reference price of $90.74 per unit, bringing his total reported holdings of this derivative instrument to 231 units.
The award represents director fees credited to a stock equivalent unit account under a grantor trust established by the director. These units track Abbott common share performance and are paid in cash, generally at age 65 or upon retirement from the board, rather than involving open-market share purchases or sales.
Abbott Laboratories director Nita Ahuja received a grant of 347 stock equivalent units on Common Shares as director compensation. These units, valued using a reference price of $90.74 per unit, increased her stock equivalent unit balance to 450 units. Director fees are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. The units earn the same return as if the fees were invested in Abbott shares, and the balance also includes units acquired through a dividend reinvestment feature.
Abbott Laboratories executive vice president Louis H. Morrone reported a routine tax-withholding transaction in company stock. On the reported date, 269 common shares were withheld at $92.71 per share to cover tax obligations, leaving him with 76,574 common shares held directly. He also has an indirect holding of 12 common shares through a profit sharing trust, reflecting the balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2026.
Abbott Laboratories executive Elizabeth C. Cushman reported a routine tax-related share disposition. On this Form 4, she surrendered 560 common shares at a value of $94.12 per share to cover tax obligations.
After this tax-withholding disposition, she directly holds 38,013 Abbott common shares, so the transaction represents a small portion of her overall reported holdings and does not reflect an open-market sale.
Abbott Laboratories director John G. Stratton reported an open-market purchase of 2,000 common shares on May 7, 2026 at a price of $86.82 per share. Following this transaction, he directly owns 23,319 common shares of Abbott Laboratories.
Abbott Laboratories executive Mary K. Moreland, an Executive Vice President, reported updated holdings of common shares. A discretionary transaction under Rule 16b-3(f) involved 5,314 common shares in a Profit Sharing Trust at $94.41 per share, leaving 17,159 shares held indirectly in the trust as of April 28, 2026. A separate holding entry shows 104,291 common shares held directly in her name. A footnote describes this as the balance in the Abbott Laboratories Stock Retirement Trust as of that date.
Conroy Kevin T reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Kevin T. Conroy received a grant of 2,286 common shares in the form of restricted stock units. These units were awarded under the Abbott Laboratories 2026 Incentive Stock Program as compensation, not through an open-market purchase.
The award will be settled one-for-one in Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, Conroy directly holds 133,737 Abbott common shares.
Stratton John G reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director John G. Stratton received an award covering 2,286 common shares as a grant of restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. Following this award, he holds 21,319 common shares directly.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. This is a compensation-related equity grant rather than an open-market share purchase.
ABBOTT LABORATORIES director Daniel J. Starks bought additional company stock and received new equity awards. He made an open-market purchase of 10,000 common shares at an average price of $92.6537 per share, bringing his direct holding to 6,751,103 common shares.
Starks also received a grant of 2,286 restricted stock units under Abbott’s 2026 Incentive Stock Program, payable one-for-one in common shares upon separation from service, death, or a change in control. In addition, he was granted stock options for 7,105 common shares at an exercise price of $91.86 per share, expiring in 2036. Separately, 258 common shares are held indirectly in the Alynne Starks 2012 Irrevocable Trust, for which he is the sole trustee.
ABBOTT LABORATORIES director Michael F. Roman received an equity award covering 2,286 common shares. The Form 4 shows this as a grant or award acquisition at a stated price of $0.00 per share, bringing his directly held stake to 10,764 common shares after the transaction.
The footnote explains this is a restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program. The units will convert one-for-one into Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program.
ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program. He was granted 2,286 restricted stock units, each convertible into one Abbott common share upon separation from service, death, or a change in control as defined in the program.
He also received an option to buy 5,929 Abbott common shares at an exercise price of $91.86 per share, expiring on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3. Following these awards, his direct holdings of Abbott common shares reported in this filing total 7,603 shares.
Abbott Laboratories director Nancy McKinstry reported equity awards rather than open-market trades. She received 2,286 restricted stock units that will convert one-for-one into common shares upon separation from service, death, or a change in control under Abbott’s 2026 Incentive Stock Program.
She also received options for 2,305 common shares at an exercise price of $91.86 per share, expiring in 2036. Following these awards, she directly holds 41,010 common shares and 2,305 options.
McDew Darren W reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Darren W. McDew received an equity award of 2,286 common shares-equivalent on a grant/award basis. The award is structured as a restricted stock unit grant under the Abbott Laboratories 2026 Incentive Stock Program and carries no cash purchase price.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, McDew directly holds 12,678 common shares, reflecting routine director compensation rather than an open-market share purchase.
Kumbier Michelle reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Michelle Kumbier received a grant of 2,286 restricted stock units. The award was made in the form of common shares without par value at no purchase price and is part of Abbott’s 2026 Incentive Stock Program.
The restricted stock units will be paid in Abbott common shares on a one-to-one basis upon the earlier of Kumbier’s separation from service, death, or a change in control as defined in the program. Following this grant, she directly holds 18,000 Abbott common shares.
Abbott Laboratories director Patricia Paola Gonzalez received an equity award tied to 2,286 common shares. The Form 4 shows an acquisition coded as a grant or award, with no cash price per share, reflecting stock-based compensation rather than an open-market purchase.
According to the footnote, this is a restricted stock unit award under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this award, Gonzalez directly holds 9,205 common shares.
Blount Sally E. reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Sally E. Blount received a grant of 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program. Each unit will be paid in one Abbott common share on the earlier of her separation from service, death, or a defined change in control. Following this award, she holds 36,344 common shares directly.
Babineaux-Fontenot Claire reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Claire Babineaux-Fontenot received a grant of 2,286 common shares on April 24, 2026, recorded at a price of $0.00 per share, as a stock-based award. Following this grant, she directly holds 7,603 Abbott common shares.
The award is structured as restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. According to the terms, the units will be settled on a one-for-one basis in Abbott common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Nita Ahuja received an equity award of 2,286 common shares-equivalent as a restricted stock unit grant. The award was granted at a price of $0.00 per share under the Abbott Laboratories 2026 Incentive Stock Program.
The units will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. Following this grant, Ahuja’s reported direct holdings total 2,286 common shares.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported multiple common share holdings and transactions dated April 23, 2026. A key event was an open-market purchase of 2,200 common shares at $91.50 per share, held indirectly through his spouse.
The filing also shows a discretionary transaction under Rule 16b-3(f) involving 8,909 common shares at $92.04 per share in a profit sharing trust, bringing that trust’s balance to 9,276 shares as of that date. Separately, Boudreau reports 71,172 common shares held directly after these transactions.
ABBOTT LABORATORIES director John G. Stratton received a grant of 382 stock equivalent units as board compensation. The units were credited on the basis of a reference price of $102.67 per unit and are held in a stock equivalent unit account under a grantor trust established by the director.
The stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in Abbott common shares, including a dividend reinvestment feature. Following this award, Stratton’s balance in the account totals 13,489 stock equivalent units. This is a non‑market, compensation-related acquisition rather than an open-market share purchase or sale.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 367 stock equivalent units on Abbott shares as part of his director compensation. These units are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. Following this award, his balance totals 6,283 stock equivalent units, which earn the same return as if the underlying fees were invested in Abbott common shares, including units acquired through a dividend reinvestment feature.
Gonzalez Patricia Paola reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Patricia Paola Gonzalez received a grant of 321 Stock Equivalent Units as director compensation. These units were credited on March 31, 2026 at a reference value of $102.67 per unit and track the value of Abbott common shares.
The grant increased her balance to 5,558 Stock Equivalent Units, including amounts accumulated through a dividend reinvestment feature. The units are held in a grantor trust and are generally paid in cash around age 65 or upon retirement from the board, rather than being traded in the open market.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Robert J. Alpern received a grant of 76 stock equivalent units on March 31, 2026 as part of his director compensation. These units are valued at $102.67 per unit and track the return of Abbott common shares.
The units are credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at age 65 or upon retirement from the board. After this award and dividend reinvestment activity, his balance totals 10,544 stock equivalent units in this account.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Nita Ahuja received a grant of stock equivalent units as part of her board compensation. On this Form 4, she was awarded 102 stock equivalent units, each priced at $102.67, credited to a stock equivalent unit account.
The footnote explains these director fees are credited to the account and generally paid in cash at age 65 or upon retirement from the board, earning the same return as if invested in Abbott common shares. Following this grant, her reported balance in this account is 102 stock equivalent units.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A received a grant of 13,255 common shares as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with one-half vesting in any one year beginning on March 23, 2027.
Following this grant, he directly holds 50,493 common shares. The award includes the right to have shares withheld to cover tax obligations rather than paying taxes in cash.
Abbott Laboratories senior vice president Eric Shroff reported two stock transactions involving Abbott common shares. On March 2, 2026, he completed an open-market sale of 709 shares at a price of $115.58 per share, leaving him with 39,164 directly held shares afterward.
On February 27, 2026, he disposed of 1,384 shares at $116.26 per share to cover tax withholding obligations, a non-market transaction typically linked to equity compensation. Both holdings are reported as direct ownership of common shares without par value.
Abbott Laboratories executive Christopher J. Scoggins reported a tax-related share disposition. On February 27, 2026, he had 4,997 common shares withheld at $116.26 per share in a tax-withholding disposition, classified under code F as payment of tax liability by delivering securities.
After this non-open-market transaction, Scoggins’ directly owned holdings in Abbott Laboratories common shares were reported as 77,126 shares.
Abbott Laboratories executive Daniel Gesua Sive Salvadori, EVP and Group President, reported two share transactions. On March 2, 2026, he executed an open-market sale of 885 common shares at $115.58 per share. On February 27, 2026, he disposed of 6,615 shares at $116.26 per share to satisfy tax-withholding obligations. Following these transactions, he directly holds 146,377 Abbott common shares.
Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026. After this sale, his directly held stake was 76,843 common shares.
On February 27, 2026, 4,040 common shares were disposed of at $116.26 per share to cover tax withholding obligations rather than as an open‑market sale. The filing also notes 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.
ABBOTT LABORATORIES Executive Vice President Mary K. Moreland reported insider share transactions. On March 2, 2026, she completed an open-market sale of 613 common shares at $115.58 per share. On February 27, 2026, 4,630 common shares were disposed of at $116.26 per share to cover tax liabilities by delivering shares.
After these transactions, her directly held common shares totaled 104,291. In addition, 11,845 common shares were held indirectly through a Profit Sharing Trust, with that trust balance reported as of February 27, 2026.
Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares. On March 2, 2026, he completed an open-market sale of 585 shares at $115.58 per share. On February 27, 2026, he disposed of 1,142 shares at $116.26 per share to cover tax obligations by delivering shares rather than cash. After these transactions, he held 24,628 common shares directly. A separate indirect holding of 58 shares was reported in a Profit Sharing Trust, with the balance noted as of February 27, 2026.
Abbott Laboratories Chairman and CEO Robert B. Ford reported a tax-related share disposition. On February 27, 2026, he disposed of 30,308 common shares at $116.26 per share through a tax-withholding transaction, a method used to satisfy tax obligations rather than an open-market sale.
After this transaction, Ford held 306,461 common shares directly. In addition, 216,203 common shares were held indirectly through the Ford Family Trust, where he serves as co-trustee, reflecting an additional layer of beneficial ownership separate from his direct holdings.
ABBOTT LABORATORIES executive Lisa D. Earnhardt, EVP and Group President, reported a tax-withholding disposition of 8,577 common shares on February 27, 2026. The shares were valued at $116.26 per share for tax purposes, and she held 90,407 shares directly after this transaction.
Abbott Laboratories executive Elizabeth C. Cushman reported two share dispositions. On March 2, she completed an open-market sale of 263 common shares at $115.58 per share, leaving her with 38,573 shares held directly.
On February 27, she disposed of 1,421 shares at $116.26 per share to cover tax obligations through a tax-withholding transaction, rather than a traditional sale. Both transactions involve Abbott common shares without par value and reflect routine insider activity by the company’s EVP, General Counsel and Secretary.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported a tax-related share disposition. On February 27, 2026, 7,441 common shares were surrendered at $116.26 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 71,172 common shares and indirectly held 366 shares through a Profit Sharing Trust as of that date.
Abbott Laboratories Senior Vice President Eric Shroff reported equity awards that increase his direct holdings. He received an option for 44,821 shares at an exercise price of $0.00 and a grant of 10,873 common shares, both characterized as awards or other acquisitions.
The 10,873-share grant is a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program with a three-year term and no more than one-third vesting in any year, tied to a minimum return on equity target. The 44,821-share employee stock option, also under the 2017 program, becomes exercisable in annual increments of 14,940 shares on February 24, 2027 and February 24, 2028, and 14,941 shares on February 24, 2029.
ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares. He received an employee stock option for 76,273 common shares at an exercise price of $0.0000 per share, granted under the Abbott Laboratories 2017 Incentive Stock Program.
The option becomes exercisable in three annual increments of 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029. He was also granted 18,502 common shares as a performance-based restricted stock award with a three-year term, with no more than one‑third vesting in any year upon Abbott reaching a minimum return on equity target, and the award allows shares to be withheld for taxes.
ABBOTT LABORATORIES executive Daniel Gesua Sive Salvadori reported awards of equity-based compensation. He received an option to buy 89,226 Abbott shares at an exercise price of $0.00 per share under the 2017 Incentive Stock Program, with the option becoming exercisable in three equal annual installments of 29,742 shares on February 24, 2027, February 24, 2028, and February 24, 2029. He also acquired 21,644 common shares as a performance-based restricted stock award with a three-year term, where no more than one-third of the award can vest in any one year, subject to Abbott reaching a minimum return on equity target, and the award allows shares to be withheld to cover taxes.
ABBOTT LABORATORIES executive Louis H. Morrone reported equity awards granted on February 24, 2026. He acquired an option to buy 63,561 Abbott shares at an exercise price of $0.00 per share and a grant of 15,418 common shares, both reported as direct ownership.
The 15,418-share award is performance-based restricted stock under the Abbott Laboratories 2017 Incentive Stock Program with a 3‑year term, where no more than one‑third can vest in any year and vesting depends on Abbott reaching a minimum return on equity target, and it allows shares to be withheld for taxes. The stock option, also under the 2017 Incentive Stock Program, was granted in a transaction exempt from Section 16 under Rule 16b‑3 and becomes exercisable in three equal annual installments of 21,187 shares on February 24, 2027, February 24, 2028, and February 24, 2029. The filing also notes an indirect holding of 12 Abbott shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.
Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.
Abbott Laboratories executive John A. McCoy Jr., Vice President and Controller, reported equity awards on February 24, 2026. He acquired an employee stock option for 22,151 options with no purchase price, which vests in three annual installments beginning in 2027. He also received a performance-based restricted stock award of 5,373 common shares that can vest over three years if Abbott meets a minimum return-on-equity target, with shares eligible to be withheld for taxes. Separately, he reported 58 common shares held indirectly in the Abbott Laboratories Stock Retirement Trust as of that date.
Abbott Laboratories Chairman and CEO Robert B. Ford reported equity awards rather than open-market trades. He acquired 344,066 options with a zero-dollar grant price under the Abbott Laboratories 2017 Incentive Stock Program, scheduled to become exercisable in three equal annual installments starting on February 24, 2027.
Ford also received a performance-based restricted stock award of 83,464 common shares with a three-year term, with no more than one-third vesting in any year, contingent on Abbott reaching a minimum return-on-equity target. An additional 216,203 common shares are reported as held indirectly through the Ford Family Trust, where he serves as co-trustee.
Earnhardt Lisa D reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive Lisa D. Earnhardt, EVP and Group President, reported equity awards on February 24, 2026. She was granted stock options covering 111,533 options and a performance-based restricted stock award of 27,056 common shares under the Abbott Laboratories 2017 Incentive Stock Program.
The restricted stock award has a three-year term, with no more than one-third vesting in any year and vesting tied to Abbott reaching a minimum return-on-equity target. The award allows shares to be withheld for taxes. The stock option becomes exercisable in increments of 37,177 and 37,178 shares on February 24, 2027, February 24, 2028, and February 24, 2029.